ランキングに戻る

DENTSPLY SIRONA Inc. (XRAY)

割安
HealthcareMedical Instruments & SuppliesUnited States

ファンダメンタル

53

株価

$8.78

時価総額

$1.90B

パート1 · 企業の価値

概要

Dentsply Sirona makes the equipment and consumable products dentists use every day: imaging systems, treatment chairs, drills and handpieces, plus the fillings, cements, orthodontic aligners and implants that go into patients' mouths. It sells almost entirely through the practices that treat patients, not directly to consumers, and its product groups span everything from a single filling to a full digital dental chair, mostly through independent distributors.

収益の仕組み

Revenue comes from selling hardware and consumables to dental and orthodontic practices, largely through independent distributors such as Henry Schein and Patterson Companies rather than directly. Equipment like imaging systems and treatment chairs is a one-time or infrequent capital purchase; consumables like fillings, cements and aligner materials are repeat purchases tied to how many patients a practice treats. The distributor relationship means Dentsply Sirona's own sales force influences demand but rarely closes the final sale.

需要を左右する要因

中程度の景気循環性

Routine dental care is fairly steady — people keep needing fillings and cleanings regardless of the economy — which supports demand for consumables. But the equipment side is more discretionary: practices can defer buying a new imaging system or chair in a weak economy, so Dentsply Sirona's results move with dental-practice capital spending as much as with patient volume.

主なリスク

  • Distributor concentration — Two distributors, Henry Schein and Patterson, together account for around a fifth or more of net sales; losing or straining either relationship would disrupt how products reach practices.
  • Product liability and recalls — Dental devices and materials carry inherent liability and recall risk; a quality issue with a widely used product could trigger a costly recall and reputational damage.
  • Regulatory compliance across markets — The company operates under extensive and changing medical-device and product regulations in many countries, and failing to comply can bring civil or criminal penalties.
  • Litigation and IP disputes — The company faces ongoing litigation risk, including securities claims, government investigations and patent disputes that can be costly to defend regardless of outcome.

顧客集中度

主要顧客が売上高の13%を占める

For 2025, distributor Henry Schein accounted for 13% of net sales and Patterson Companies for just under 10%; Dentsply Sirona sells most of its products through a small number of large distributors rather than directly to practices.

強気材料

Buyers argue that Dentsply Sirona's product lines make it one of the few suppliers able to equip an entire dental practice, that recurring consumables sales cushion swings in equipment demand, and that recent segment reshuffling and cost cuts position the company to improve margins once dental capital spending recovers.

弱気材料

Sellers worry that the company competes in a fragmented dental-products market with no single dominant brand, that two distributors control a meaningful share of how its products reach practices, and that recent goodwill impairments in two of its segments signal the underlying businesses are worth less than once assumed.

Written by the editors, published on 2026年8月18日

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

貸借対照表と流動性

売上高

$3.64B

直近12か月(2026/6/30まで)

純利益

$-546M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$104M

自己資本合計

$1.34B

負債合計

$4.09B

流動比率

1.63

利払い倍率

3.41

負債/EBITDA

-

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割安

適正価値

$31.07

現在株価

$8.78

安全マージン

+71.8%

適正価値レンジ

$20.20 - $41.95

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$13.53
ディスカウンテッド・キャッシュフロー(DCF):$57.38
利益倍率(P/E):算出に必要なデータが不足しています
グレアムの成長公式:算出に必要なデータが不足しています
収益力価値(EPV):算出に必要なデータが不足しています
正当化されたP/B:算出に必要なデータが不足しています
配当割引モデル(ゴードン):$9.62
P/FFO(運用から生まれる資金):算出に必要なデータが不足しています
中間サイクル利益:$31.35
売上高倍率:$71.31
アナリスト・コンセンサス:保有 (8B / 13H / 2S)
直近の決算サプライズ:+46.15%

バリュエーション指標

P/E レシオ

-

ROE

-44.7%

P/B レシオ

1.29

P/FCF

12.18

粗利益率

49.5%

ROIC

-6.1%

収益性レーダー

価値創造(経済的モート)

ROIC

-6.1%

WACC

5.9%

ROIC − WACC

-12.0 pp

ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。

ファンダメンタル分析基準

合格(12)

  • Gross Margin 49.5%
  • P/FCF 12.18
  • P/B Ratio 1.29
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • DCF valuation (Undervalued)
  • Earnings Surprise avg 4.3%
  • Share Dilution -1.9%
  • Net Margin Trend -15.0% vs -25.9%
  • Piotroski F-Score 6/9

不合格(10)

  • EPS shows upward trend
  • Price CAGR -16.27%
  • ROIC -6.1%
  • Operating Margin -8.5%
  • CapEx intensity
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE -39.8%
  • Revenue Growth 5Y 2.0%
  • Analyst Consensus 35% Buy

データなし(5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-スコア

6/9

まちまちのシグナル:一部の領域に注意が必要

score
criteria

利益の質

-

低品質:会計処理を調査してください

株式希薄化

-1.9%

株式を買い戻している。株主に友好的

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. Daniel T. ScavillaPresident, CEO, Interim Principal Financial Officer & Director60
Ms. Andrea L. FrohningSenior VP & Chief Human Resources Officer55
Mr. Robert Anthony JohnsonSenior VP & Chief Supply Chain Officer56
Mr. Aldo M. DentiExecutive VP & Chief Commercial Officer57
Mr. John C. FortsonExecutive VP & CFO58
Mr. Kevin J. CzerneyVice President & Chief Accounting Officer41
Mr. Kevin BoyleSenior VP & Chief Technology Officer-
Wade MoodySenior Manager of Investor Relations-
Ms. Lindi Barton-BrobstSenior VP & General Counsel-
Ms. Emily P. MinerSenior Vice President & Chief Quality Officer-

監査リスク

1

取締役会リスク

3

報酬リスク

5

株主権利リスク

1

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-02-26

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-08-06

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-08-06

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for XRAY, sourced from Markets Gazette.

  • 3/13/2026POSITIVE
    Is Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?

    A director at Dentsply Sirona Inc. has purchased 15,000 shares, signaling strong insider confidence in the dental technology firm. This move comes after a period of share price decline for the company, which is known for its robust recurring revenue streams. The insider transaction suggests that at least one key executive believes the stock is undervalued and poised for a recovery. Investors often view significant insider buying as a positive indicator, potentially preceding a turnaround or a period of sustained growth.

  • 2/27/2026NEUTRAL
    DENTSPLY SIRONA (XRAY) Q4 2025 Earnings Transcript

    The market eagerly anticipates the release of the Q4 2025 earnings call transcript for DENTSPLY SIRONA (XRAY). While the specific content is not yet available, investor attention remains high for this crucial event. Quarterly earnings reports are fundamental for assessing a company's financial health, its performance against expectations, and the future outlook provided by management. Analysts and investors will be looking for insights into revenue, profitability, and, critically, guidance for upcoming periods. The current lack of details keeps the stock in a holding pattern, with potential significant movements once key information is disclosed. The transparency and data provided in these transcripts are essential for shaping investment decisions and understanding DENTSPLY SIRONA's strategic trajectory in the dental technology sector.

via Markets Gazette